Pdt Partners, LLC Verve Therapeutics, Inc. Transaction History

Pdt Partners, LLC

$1 Billion
Q4 2024

A detailed history of Pdt Partners, LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 53,291 shares of VERV stock, worth $387,958. This represents 0.03% of its overall portfolio holdings.

Number of Shares

53,291

Previous 181,803 70.69%

Holding current value

$387,958

Previous $879,000 65.87%

% of portfolio

0.03%

Previous 0.09%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$4.5 - $7.19 $578,304 - $924,001	-128,512 Reduced 70.69%	53,291 $300,000
Q3 2024 Nov 14, 2024	SELL	$4.4 - $7.86 $669,068 - $1.2 Million	-152,061 Reduced 45.55%	181,803 $879,000
Q2 2024 Aug 15, 2024	BUY	$4.76 - $12.79 $681,898 - $1.83 Million	143,256 Added 75.16%	333,864 $1.63 Million
Q1 2024 May 15, 2024	BUY	$10.81 - $17.96 $1.3 Million - $2.15 Million	119,979 Added 169.87%	190,608 $2.53 Million
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $624,360 - $1.32 Million	70,629 New	70,629 $984,000

Others Institutions Holding VERV

# of Institutions

180

Shares Held

76.4M

Call Options Held

70.3K

Put Options Held

194K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $436M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account